Loading...
•
Dec 31, 2020
Bioxcel Therapeutics Q4 2020 Earnings Report
BioXcel Therapeutics reported fourth quarter and full year 2020 financial results.
Key Takeaways
BioXcel Therapeutics reported a net loss of $21.1 million for the fourth quarter of 2020, compared to a net loss of $8.3 million for the same period in 2019. As of December 31, 2020, cash and cash equivalents totaled approximately $213.1 million.
NDA submitted to the U.S. Food and Drug Administration for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501
End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021